Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Topotecan and gemcitabine are drugs globally registered for recurrent ovarian carcinoma. This
trial will determine the maximum tolerated dose and the efficacy of this combination
administered weekly in patients with platinum -resistant ovarian cancer.